Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...
Contract Pharma7h
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Pharmaceutical Technology1mon
Risk adjusted net present value: What is the current valuation of AnaptysBio’s Imsidolimab?
The revenue for Imsidolimab is expected to reach an annual total of $22 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Vanda, Anaptys Join on Development Pact
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...
ADVFN20d
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
In the 45-patient GEMINI-1 Phase 3 trial, patients were randomized 1:1:1 to receive a single infusion of 750mg intravenous (IV) imsidolimab, 300mg IV imsidolimab or placebo at Day 0. Of the ...
CNN4y
AnaptysBio, Inc.
engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic ...